Paper42467182
18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers.
Imabayashi E and 5 others. Ann Nucl Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. 18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers. Papers, record 42467182. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42467182
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carbolines | Major topic |
| Positron-Emission Tomography | Major topic |
| East Asian People | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Japan | |
| Tissue Distribution |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Eli Lilly and Company | Eli Lilly and Company | PubMed | ||
| Avid Radiopharmaceuticals | Avid Radiopharmaceuticals | PubMed |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03901092 | A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04474405 | Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects | Derived from the trial | Yes | ClinicalTrials.gov |
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39776249 | Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/39776249 | PubMed |
| 2 | 26728162 | Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology. | Mol Imaging Biol | 2016 | https://conductscience.org/library/papers/26728162 | PubMed |
| 3 | 33986301 | Alzheimer disease. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/33986301 | PubMed |
| 4 | 33573211 | Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/33573211 | PubMed |
| 5 | 38733347 | Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy. | Protein Cell | 2025 | https://conductscience.org/library/papers/38733347 | PubMed |
| 6 | 843571 | The measurement of observer agreement for categorical data. | Biometrics | 1977 | https://conductscience.org/library/papers/843571 | PubMed |
| 7 | 36855201 | Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. | Alzheimers Res Ther | 2023 | https://conductscience.org/library/papers/36855201 | PubMed |
| 8 | 37748892 | Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies. | Neurology | 2023 | https://conductscience.org/library/papers/37748892 | PubMed |
| 9 | 41739230 | Disentangling on and off-target binding in flortaucipir PET: a voxel-to-voxel P-tau, ferric iron, and MAO-B histology-to-flortaucipir PET comparison. | Acta Neuropathol | 2026 | https://conductscience.org/library/papers/41739230 | PubMed |
| 10 | 32338734 | Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. | JAMA Neurol | 2020 | https://conductscience.org/library/papers/32338734 | PubMed |
| 11 | 35596745 | Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35596745 | PubMed |
| 12 | 37459141 | Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37459141 | PubMed |
| 13 | 29449700 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. | Nat Rev Neurol | 2018 | https://conductscience.org/library/papers/29449700 | PubMed |
| 14 | 38934362 | Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. | Alzheimers Dement | 2024 | https://conductscience.org/library/papers/38934362 | PubMed |
| 15 | 33587110 | Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/33587110 | PubMed |
| 16 | 38187878 | A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles. | Brain Commun | 2024 | https://conductscience.org/library/papers/38187878 | PubMed |
| 17 | 26505746 | Tau positron emission tomographic imaging in aging and early Alzheimer disease. | Ann Neurol | 2016 | https://conductscience.org/library/papers/26505746 | PubMed |
| 18 | 23948934 | Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. | J Alzheimers Dis | 2014 | https://conductscience.org/library/papers/23948934 | PubMed |
| 19 | 22265587 | National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. | Alzheimers Dement | 2012 | https://conductscience.org/library/papers/22265587 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 |
Source NCBI Gene
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| FLORBETAPIR | CHEMBL1908919 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1908919 | ChEMBL |
| FLORTAUCIPIR F 18 | CHEMBL3545253 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3545253 | ChEMBL |
| FLORTAUCIPIR | CHEMBL3546271 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3546271 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Cited by
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42467182
GET https://conductscience.org/api/papers/v1/42467182/authors